Lung Cancer Trials Ask AI to find trials
RecruitingPhase 1NCT07164313
Official study title

A Study of ZW251 in Participants With Advanced Solid Tumors

Study summary

The purpose of this study is to find out if ZW251, an antibody-drug conjugate targeting glypican-3 (GPC3), is safe and can treat participants with advanced cancers, including hepatocellular carcinoma (HCC), squamous cell non-small cell lung cancer (NSCLC), or germ cell tumors (GCT).

Ask AI to explain this study
Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedZW251

The study team can explain what participation involves.

Who it may be forNon-small cell lung cancer (NSCLC)

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 5, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Phase 1

Interventional

Where is it offered?25 U.S. locations

Locations may change over time.

Who runs it?Zymeworks BC Inc.

Study sponsor

01
Study overview

What this study is about

Purpose
Treatment
Study type
Interventional
Phase
Phase 1
Sponsor
Zymeworks BC Inc.
Interventions being studied
Drug: ZW251
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type
Non-small cell lung cancer (NSCLC)→
03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Pathologically or cytologically confirmed diagnosis of HCC with evidence of locally advanced (unresectable, and ineligible for transplant) and/or metastatic disease. Noninvasive methods may be used to confirm diagnosis
  • Pathologically or cytologically confirmed diagnosis of squamous cell NSCLC with evidence of locally advanced (unresectable) and/or metastatic disease
  • Pathologically or cytologically confirmed diagnosis of GCT with evidence of yolk sac and/or choriocarcinoma predominant component and locally advanced (unresectable) and/or metastatic disease
  • Measurable disease per RECIST v1.1
  • Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
  • Liver function status of Child-Pugh Class A (for HCC only)
  • Adequate organ function
Reasons someone may not be able to joinExclusion criteria
  • Known additional malignancy that is progressing or that has required active treatment within the last year
  • History of hepatic encephalopathy within the past 6 months or requirement for medications to control encephalopathy
  • Participants with HCC experiencing main portal vein tumor invasion require sponsor approval for enrollment
  • Known gastrointestinal bleeding within 3 months
  • Acute or chronic uncontrolled renal disease, pancreatitis, or non-malignant liver disease

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • UCSF Comprehensive Cancer CenterSan Francisco, California
  • University of California Los Angeles - Cancer Care - Santa Monica (UCLA)Santa Monica, California
  • Norton Cancer InstituteLouisville, Kentucky
  • START MidwestGrand Rapids, Michigan
  • Hackensack University Medical CenterHackensack, New Jersey
  • Memorial Sloan Kettering Cancer CenterNew York, New York
  • MD Anderson Cancer CenterHouston, Texas
  • START San AntonioSan Antonio, Texas
  • START - Dublin Mater Misericordiae University Hospital (MMUH)Dublin
  • National Cancer Center EastKashiwa
  • Kyoto University HospitalKyoto
  • Kansai Medical University HospitalOsaka

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 5, 2026. Always confirm current availability with the study team.

View original record ↗